Stem Cell Innovations Signs Compound Validation Collaboration with H. Lundbeck
Complete the form below to unlock access to ALL audio articles.
Stem Cell Innovations, Inc. has announced that it had entered into an agreement to examine hepatic metabolism of a set of Lundbeck compounds using its proprietary C3A human liver cell-line.
Lundbeck is a research-based pharmaceutical company, engaged in research to find new drugs for treatment of CNS disorders.
“This new collaboration shows the expanding acceptance of our C3A cell-line as an excellent platform to study human liver function,” said Stem Cell Innovations’ CEO Dr. James Kelly.
“Our protected C3A cell system has intact human liver machinery, is robust and thoroughly quality controlled, all the prerequisites for larger scale in vitro efficacy and safety programs,” Kelly added.
C3A is SCI’s patented human liver cell line, originally developed for use in an artificial liver used to support patients waiting for transplantation. The cells exhibit a wide variety of human liver functions and are ideal for use in examining the effects of new drugs on the human liver.
The application of SCI’s ACTIVTox system, based on the C3A cell line, can lead to better drugs with a decreased likelihood of causing liver toxicity.
